

CCC-DTS Publicationlist

1. Vasicek J, Shehata M, Schnabl S, Hilgarth M, Hubmann R, Jager U, Bauer M, Chrenek P: Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells. *Biotechnology progress* 2018, 34(5):1278-1289.
2. Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M et al: Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. *Wiener klinische Wochenschrift* 2018.
3. Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jager U et al: Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model. *Frontiers in pharmacology* 2017, 8:319.
4. Steinmetz B, Hackl H, Slabakova E, Schwarzingler I, Smejova M, Spittler A, Arbesu I, Shehata M, Soucek K, Wieser R: The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid. *Cell cycle* 2014, 13(18):2931-2943.
5. Porpaczy E, Tauber S, Bilban M, Kostner G, Gruber M, Eder S, Heintel D, Le T, Fleiss K, Skrabs C et al: Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance. *Leukemia research* 2013, 37(6):631-636.
6. Hubmann R, Hilgarth M, Schnabl S, Ponath E, Reiter M, Demirtas D, Sieghart W, Valent P, Zielinski C, Jager U et al: Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. *British journal of haematology* 2013, 160(5):618-629.
7. Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, Le T, Zehetmayer S, Mannhalter C, Gaiger A et al: Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. *Blood* 2013, 121(7):1175-1183.
8. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L et al: PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. *Nature medicine* 2012, 18(11):1699-1704.
9. Gruber M, Fleiss K, Porpaczy E, Skrabs C, Hauswirth AW, Gaiger A, Vanura K, Heintel D, Shehata M, Einberger C et al: Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. *Annals of hematology* 2011, 90(10):1131-1136.
10. Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E, Badrnya S, Lehner C, Hoelbl A, Duechler M et al: Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. *Blood* 2010, 116(14):2513-2521.
11. Shehata M, Demirtas D, Schnabl S, Hilgarth M, Hubmann R, Fonatsch C, Schwarzingler I, Hopfinger G, Eigenberger K, Heintel D et al: Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. *Leukemia* 2010, 24(12):2122-2127.
12. Schulenburg A, Bramswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C et al: Neoplastic stem cells: current concepts and clinical perspectives. *Critical reviews in oncology/hematology* 2010, 76(2):79-98.

13. Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E et al: [Tumor stem cell research - basis and challenge for diagnosis and therapy]. *Wiener klinische Wochenschrift* 2010, 122(13-14):423-436.
14. Hubmann R, Duchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Holbl A, Vanura K, Le T, Look T et al: NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. *British journal of haematology* 2010, 148(6):868-878.
15. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ et al: Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. *Blood* 2009, 114(20):4441-4450.
16. Geyeregger R, Shehata M, Zeyda M, Kiefer FW, Stuhlmeier KM, Porpaczy E, Zlabinger GJ, Jager U, Stulnig TM: Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes. *Journal of leukocyte biology* 2009, 86(5):1039-1048.
17. Vanura K, Le T, Esterbauer H, Spath F, Porpaczy E, Shehata M, Eigenberger K, Hauswirth A, Skrabs C, Kromer E et al: Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. *Haematologica* 2008, 93(12):1912-1916.
18. Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W et al: New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. *British journal of cancer* 2008, 99(1):151-159.
19. Jäger U SM, Heintel D, Hubmann R, Kainz B, Porpaczy E, Hauswirth A, Gaiger A.: Genetics in CLL: Impact for prognosis and treatment decisions. . *Haematologica* 2007:7.
20. Wohrer S, Rabitsch W, Shehata M, Kondo R, Esterbauer H, Streubel B, Sillaber C, Raderer M, Jaeger U, Zielinski C et al: Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. *Anticancer research* 2007, 27(6B):3837-3841.
21. Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Kromer-Holzinger E, Le T, Krober A, Heller G, Schwarzinger I et al: Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. *International journal of cancer* 2007, 121(9):1984-1993.
22. Smolewski P, Duechler M, Linke A, Cebula B, Grzybowska-Izydorczyk O, Shehata M, Robak T: Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. *Leukemia research* 2006, 30(12):1521-1529.
23. Shehata M, Schwarzmeier JD, Hilgarth M, Demirtas D, Richter D, Hubmann R, Boeck P, Leiner G, Falkenbach A: Effect of combined spa-exercise therapy on circulating TGF-beta1 levels in patients with ankylosing spondylitis. *Wiener klinische Wochenschrift* 2006, 118(9-10):266-272.
24. Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A et al: Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. *Cytometry Part B, Clinical cytometry* 2006, 70(4):309-314.
25. Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M et al: Deregulated expression of fat and muscle genes in B-cell chronic

lymphocytic leukemia with high lipoprotein lipase expression. *Leukemia* 2006, 20(6):1080-1088.

26. Schwarzmeier JD, Hubmann R, Duchler M, Jager U, Shehata M: Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia. *Leukemia & lymphoma* 2005, 46(2):157-165.

27. Kees M, Wiesbauer F, Gisslinger B, Wagner R, Shehata M, Gisslinger H: Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. *Thrombosis and haemostasis* 2005, 93(1):70-75.

28. Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C et al: High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. *Leukemia* 2005, 19(7):1216-1223.

29. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R: Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. *Leukemia* 2005, 19(2):260-267.

30. Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, Smolewski P: In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. *European journal of haematology* 2005, 74(5):407-417.

31. Schwarzmeier JD, Hamwi A, Preisel M, Resl C, Preusser M, Sluga E, Horcher E, Shehata MM: Positive troponin T without cardiac involvement in inclusion body myositis. *Human pathology* 2005, 36(8):917-921.

32. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H: TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. *The Journal of clinical investigation* 2004, 113(5):676-685.

33. Schwarzmeier JD, Shehata M, Ackermann J, Hilgarth M, Kaufmann H, Drach J: Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: evaluation by FISH analysis and in vitro expansion of bone marrow cells. *Leukemia* 2003, 17(7):1426-1428.

34. Schwarzmeier JD, Shehata M, Hilgarth M, Marschitz I, Louda N, Hubmann R, Greil R: The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. *Leukemia & lymphoma* 2002, 43(3):549-554.

35. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M, Berger R: Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. *Blood* 2002, 99(10):3742-3747.

36. Filipic B, Shehata M, Toth S, Schwarzmeier J, Koren S: Novel serum replacement based on bovine ocular fluid: a useful tool for cultivation of different animal cells in vitro. *Altex* 2002, 19(1):15-20.

37. Derhaschnig U, Shehata M, Herkner H, Bur A, Woisetschlager C, Laggner AN, Hirschl MM: Increased levels of transforming growth factor-beta1 in essential hypertension. *American journal of hypertension* 2002, 15(3):207-211.

38. Shehata M, Schwarzmeier JD, Nguyen ST, Hilgarth M, Berger R, Hubmann R, Kickmaier S, Decker T: Reconstitution of endogenous interferon alpha by recombinant interferon in hairy cell leukemia. *Cancer research* 2000, 60(19):5420-5426.

39. Gruber G, Schwarzmeier JD, Shehata M, Hilgarth M, Berger R: Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. *Blood* 1999, 94(3):1077-1085.

40. Schwarzmeier JD, Hilgarth M, Nguyen ST, Shehata M, Gruber G, Spittler A, Willheim M, Boltz-Nitulescu G, Hocker P, Berger R: Inadequate production of hematopoietic growth factors in hairy cell leukemia: up-regulation of interleukin 6 by recombinant IFN-alpha in vitro. *Cancer research* 1996, 56(20):4679-4685.

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23]
[24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40]

1. Vasicek J, Shehata M, Schnabl S, Hilgarth M, Hubmann R, Jager U, Bauer M, Chrenek P: **Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells.** *Biotechnology progress* 2018, **34**(5):1278-1289.
2. Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M *et al*: **Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.** *Wiener klinische Wochenschrift* 2018.
3. Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jager U *et al*: **Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.** *Frontiers in pharmacology* 2017, **8**:319.
4. Steinmetz B, Hackl H, Slabakova E, Schwarzingler I, Smejova M, Spittler A, Arbesu I, Shehata M, Soucek K, Wieser R: **The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.** *Cell cycle* 2014, **13**(18):2931-2943.
5. Porpaczy E, Tauber S, Bilban M, Kostner G, Gruber M, Eder S, Heintel D, Le T, Fleiss K, Skrabs C *et al*: **Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance.** *Leukemia research* 2013, **37**(6):631-636.
6. Hubmann R, Hilgarth M, Schnabl S, Ponath E, Reiter M, Demirtas D, Sieghart W, Valent P, Zielinski C, Jager U *et al*: **Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells.** *British journal of haematology* 2013, **160**(5):618-629.
7. Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, Le T, Zehetmayer S, Mannhalter C, Gaiger A *et al*: **Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.** *Blood* 2013, **121**(7):1175-1183.
8. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L *et al*: **PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.** *Nature medicine* 2012, **18**(11):1699-1704.
9. Gruber M, Fleiss K, Porpaczy E, Skrabs C, Hauswirth AW, Gaiger A, Vanura K, Heintel D, Shehata M, Einberger C *et al*: **Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.** *Annals of hematology* 2011, **90**(10):1131-1136.
10. Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E, Badrnya S, Lehner C, Hoelbl A, Duechler M *et al*: **Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.** *Blood* 2010, **116**(14):2513-2521.
11. Shehata M, Demirtas D, Schnabl S, Hilgarth M, Hubmann R, Fonatsch C, Schwarzingler I, Hopfinger G, Eigenberger K, Heintel D *et al*: **Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia.** *Leukemia* 2010, **24**(12):2122-2127.
12. Schulenburg A, Bramswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C *et al*: **Neoplastic stem cells: current concepts and clinical perspectives.** *Critical reviews in oncology/hematology* 2010, **76**(2):79-98.
13. Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E *et al*: **[Tumor stem cell research - basis and challenge for diagnosis and therapy].** *Wiener klinische Wochenschrift* 2010, **122**(13-14):423-436.

14. Hubmann R, Duchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Holbl A, Vanura K, Le T, Look T *et al*: **NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells.** *British journal of haematology* 2010, **148**(6):868-878.
15. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ *et al*: **Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.** *Blood* 2009, **114**(20):4441-4450.
16. Geyeregger R, Shehata M, Zeyda M, Kiefer FW, Stuhlmeier KM, Porpaczy E, Zlabinger GJ, Jager U, Stulnig TM: **Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes.** *Journal of leukocyte biology* 2009, **86**(5):1039-1048.
17. Vanura K, Le T, Esterbauer H, Spath F, Porpaczy E, Shehata M, Eigenberger K, Hauswirth A, Skrabs C, Kromer E *et al*: **Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes.** *Haematologica* 2008, **93**(12):1912-1916.
18. Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W *et al*: **New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis.** *British journal of cancer* 2008, **99**(1):151-159.
19. Jäger U SM, Heintel D, Hubmann R, Kainz B, Porpaczy E, Hauswirth A, Gaiger A.: **Genetics in CLL: Impact for prognosis and treatment decisions.** *Haematologica* 2007:7.
20. Wohrer S, Rabitsch W, Shehata M, Kondo R, Esterbauer H, Streubel B, Sillaber C, Raderer M, Jaeger U, Zielinski C *et al*: **Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone.** *Anticancer research* 2007, **27**(6B):3837-3841.
21. Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Kromer-Holzinger E, Le T, Krober A, Heller G, Schwarzinger I *et al*: **Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia.** *International journal of cancer* 2007, **121**(9):1984-1993.
22. Smolewski P, Duechler M, Linke A, Cebula B, Grzybowska-Izydorczyk O, Shehata M, Robak T: **Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.** *Leukemia research* 2006, **30**(12):1521-1529.
23. Shehata M, Schwarzmeier JD, Hilgarth M, Demirtas D, Richter D, Hubmann R, Boeck P, Leiner G, Falkenbach A: **Effect of combined spa-exercise therapy on circulating TGF-beta1 levels in patients with ankylosing spondylitis.** *Wiener klinische Wochenschrift* 2006, **118**(9-10):266-272.
24. Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A *et al*: **Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.** *Cytometry Part B, Clinical cytometry* 2006, **70**(4):309-314.
25. Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M *et al*: **Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression.** *Leukemia* 2006, **20**(6):1080-1088.
26. Schwarzmeier JD, Hubmann R, Duchler M, Jager U, Shehata M: **Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.** *Leukemia & lymphoma* 2005, **46**(2):157-165.
27. Kees M, Wiesbauer F, Gisslinger B, Wagner R, Shehata M, Gisslinger H: **Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera.** *Thrombosis and haemostasis* 2005, **93**(1):70-75.
28. Heintel D, Kienle D, Shehata M, Krober A, Kromer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C *et al*: **High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia.** *Leukemia* 2005, **19**(7):1216-1223.

29. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R: **Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.** *Leukemia* 2005, **19**(2):260-267.
30. Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, Smolewski P: **In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.** *European journal of haematology* 2005, **74**(5):407-417.
31. Schwarzmeier JD, Hamwi A, Preisel M, Resl C, Preusser M, Sluga E, Horcher E, Shehata MM: **Positive troponin T without cardiac involvement in inclusion body myositis.** *Human pathology* 2005, **36**(8):917-921.
32. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H: **TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia.** *The Journal of clinical investigation* 2004, **113**(5):676-685.
33. Schwarzmeier JD, Shehata M, Ackermann J, Hilgarth M, Kaufmann H, Drach J: **Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: evaluation by FISH analysis and in vitro expansion of bone marrow cells.** *Leukemia* 2003, **17**(7):1426-1428.
34. Schwarzmeier JD, Shehata M, Hilgarth M, Marschitz I, Louda N, Hubmann R, Greil R: **The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.** *Leukemia & lymphoma* 2002, **43**(3):549-554.
35. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M, Berger R: **Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia.** *Blood* 2002, **99**(10):3742-3747.
36. Filipic B, Shehata M, Toth S, Schwarzmeier J, Koren S: **Novel serum replacement based on bovine ocular fluid: a useful tool for cultivation of different animal cells in vitro.** *Altex* 2002, **19**(1):15-20.
37. Derhaschnig U, Shehata M, Herkner H, Bur A, Woisetschlager C, Laggner AN, Hirschl MM: **Increased levels of transforming growth factor-beta1 in essential hypertension.** *American journal of hypertension* 2002, **15**(3):207-211.
38. Shehata M, Schwarzmeier JD, Nguyen ST, Hilgarth M, Berger R, Hubmann R, Kickmaier S, Decker T: **Reconstitution of endogenous interferon alpha by recombinant interferon in hairy cell leukemia.** *Cancer research* 2000, **60**(19):5420-5426.
39. Gruber G, Schwarzmeier JD, Shehata M, Hilgarth M, Berger R: **Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia.** *Blood* 1999, **94**(3):1077-1085.
40. Schwarzmeier JD, Hilgarth M, Nguyen ST, Shehata M, Gruber G, Spittler A, Willheim M, Boltz-Nitulescu G, Hocker P, Berger R: **Inadequate production of hematopoietic growth factors in hairy cell leukemia: up-regulation of interleukin 6 by recombinant IFN-alpha in vitro.** *Cancer research* 1996, **56**(20):4679-4685.